AUSSENDER



Biofrontera AG
Ansprechpartner: Investor Relations
Tel.: +49 (0) 214 87 63 20
E-Mail: ir@biofrontera.com
Pressefach (1282)

Rechtsgrundlage

Alle
Insiderinformationen
Unternehmensmitteilungen
Finanzberichte
Stimmrechtsmitteilungen
HV-Bekanntmachungen
Sonstige

Schlagwörter

Quartalsergebnis
DE EN
30.05.2026 - 00:15 | Biofrontera AG
BIOFRONTERA REPORTS RESULTS FOR THE FIRST QUARTER OF 2026
17.04.2026 - 23:20 | Biofrontera AG
BIOFRONTERA REPORTS RESULTS FOR THE FINANCIAL YEAR 2025
17.04.2026 - 22:50 | Biofrontera AG
Pre-announcement of a financial report according to articles 114 - 117 WpHG
10.03.2026 - 18:55 | Biofrontera AG
Financial Guidance for FY 2026
14.02.2026 - 13:15 | Biofrontera AG
Forecast Increase
28.11.2025 - 11:00 | Biofrontera AG
BIOFRONTERA REPORTS RESULTS FOR THE FIRST NINE MONTHS OF 2025
04.11.2025 - 10:20 | Biofrontera AG
Biofrontera AG signs an agreement with Propharma d.o.o. for the distribution of Ameluz® in Croatia
23.10.2025 - 16:50 | Biofrontera AG
Biofrontera AG completes sale of U.S. Ameluz® and RhodoLED® assets to Biofrontera Inc.
30.09.2025 - 22:48 | Biofrontera AG
Correction notice regarding the H1 2025 report and the corresponding press release dated September 30, 2025, 00:18 a.m.
30.09.2025 - 20:15 | Biofrontera AG
Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST HALF OF 2025
30.09.2025 - 00:22 | Biofrontera AG
BIOFRONTERA REPORTS RESULTS FOR THE FIRST HALF OF 2025
24.09.2025 - 23:10 | Biofrontera AG
Expected impairment losses
01.08.2025 - 12:05 | Biofrontera AG
Biofrontera AG: New Forecast
01.07.2025 - 01:40 | Biofrontera AG
Biofrontera Inc. Fulfills the conditions for implementing the term sheet with Biofrontera AG
30.06.2025 - 14:15 | Biofrontera AG
Secures Long-Term U.S. Market Presence Through Strategic Restructuring Agreement with Biofrontera Inc.
|
99.092 Abonnenten
|
234.660 Meldungen
|
95.040 Pressefotos
|
Folgen Sie uns auf Twitter
|
Persönlicher Kontakt